Fighting cancer with red wine? Molecular mechanisms of resveratrol

Critical Reviews in Food Science and Nutrition

Volumn 49, Issue 9, 2009, Pages 782-799

  Kraft, Thomas E ^a   Parisotto, Daniel ^a   Schempp, Christina ^a   Efferth, Thomas ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

Angiogenesis; Apoptosis; Bioavailability; Cancer; Chemoprevention; Inflammation; Resveratrol

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; RESVERATROL; STILBENE DERIVATIVE;

APOPTOSIS; ARTICLE; BIOAVAILABILITY; DRUG EFFECT; HUMAN; NEOPLASM; WINE;

ANGIOGENESIS INHIBITORS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BIOLOGICAL AVAILABILITY; HUMANS; NEOPLASMS; STILBENES; WINE;

EID: 70349859902     PISSN: 10408398     EISSN: 15497852     Source Type: Journal    
DOI: 10.1080/10408390802248627     Document Type: Article

References (214)

1. Aggarwal, B. B. (2003). Signalling pathways of the TNF superfamily: a doubleedged sword. Nat Rev Immunol. 3:745-756
2. Aggarwal, B. B., Bhardwaj, A., Aggarwal, R. S., Seeram, N. P., Shishodia, S. and Takada, Y. (2004). Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 24:2783-2840
3. Ahmad, A., Syed, F. A., Singh, S. and Hadi, S. M. (2005). Prooxidant activity of resveratrol in the presence of copper ions: mutagenicity in plasmid DNA. Toxicol Lett. 159:1-12.
4. Ahmad, N., Adhami, V. M., Afaq, F., Feyes, D. K. and Mukhtar, H. (2001). Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res. 7:1466-1473
5. Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K.,Walter, P. (2002). The Cell. Garland Science, New York.
6. Ames, B. N. (1983). Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science. 221:1256-1264
7. Amorati, R., Lucarini, M., Mugnaini, V., Pedulli, G. F., Roberti, M. and Pizzirani, D. (2004). Antioxidant activity of hydroxystilbene derivatives in homogeneous solution. J Org Chem. 69:7101-7107
8. Andlauer,W.,Kolb, J., Siebert, K. and Furst, P. (2000).Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp Clin Res. 26:47-55.
9. Athar, M., Back, J. H., Tang, X., Kim, K. H., Kopelovich, L., Bickers, D. R. and Kim, A. L. (2007). Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol. 224:274-283
10. Azmi, A. S., Bhat, S. H. and Hadi, S. M. (2005). Resveratrol-Cu(II) induced DNA breakage in human peripheral lymphocytes: implications for anticancer properties. FEBS Lett. 579:3131-3135
11. Banerjee, S., Bueso-Ramos, C. and Aggarwal, B. B. (2002). Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 62:4945-4954
12. Bargou, R. C., Emmerich, F., Krappmann, D., Bommert, K., Mapara, M. Y., Arnold, W., Royer, H. D., Grinstein, E., Greiner, A., Scheidereit, C. and Dorken, B. (1997). Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 100:2961-2969 (Pubitemid 28022832)
13. Barinaga, M. (1996). Life-death balance within the cell. Science. 274:724.
14. Baron, J. A. and Sandler, R. S. (2000). Nonsteroidal anti-inflammatory drugs and cancer prevention. Annu Rev Med. 51:511-523
15. Baur, J. A. and Sinclair, D. A. (2006). Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 5:493-506.
16. Beg, A. A. and Baltimore, D. (1996). An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science. 274:782-784
17. Benitez, D. A., Pozo-Guisado, E., Alvarez-Barrientos, A., Fernandez-Salguero, P. M. and Castellon, E. A. (2007). Mechanisms involved in resveratrolinduced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl. 28:282-293
18. Bennett, A. (1986). The production of prostanoids in human cancers, and their implications for tumor progression. Prog Lipid Res. 25:539-542
19. Bennett, A., Carroll, M. A., Stamford, I. F., Whimster, W. F. and Williams, F. (1982). Prostaglandins and human lung carcinomas. Br J Cancer. 46:888-893
20. Bennett, A., Carter,R.L., Stamford, I. F. andTanner, N. S. (1980). Prostaglandinlike material extracted from squamous carcinomas of the head and neck. Br J Cancer. 41:204-208
21. Bennett, A., Charlier, E. M., McDonald, A. M., Simpson, J. S., Stamford, I. F. and Zebro, T. (1977). Prostaglandins and breast cancer. Lancet. 2:624-626
22. Bennett, A., Tacca, M. D., Stamford, I. F. and Zebro, T. (1977). Prostaglandins from tumours of human large bowel. Br J Cancer. 35:881-884
23. Berge, G., Ovrebo, S., Botnen, I. V., Hewer, A., Phillips, D. H., Haugen, A. and Mollerup, S. (2004). Resveratrol inhibits benzo[a]pyrene-DNA adduct formation in human bronchial epithelial cells. Br J Cancer. 91:333-338
24. Berge, G., Ovrebo, S., Eilertsen, E., Haugen, A. andMollerup, S. (2004). Analysis of resveratrol as a lung cancer chemopreventive agent in A/J mice exposed to benzo[a]pyrene. Br J Cancer. 91:1380-1383
25. Bharti, A. C. and Aggarwal, B. B. (2002). Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol. 64:883-888
26. Bogaczewicz, J., Jasielski, P., Mosiewicz, A., Trojanowski, T., Suchozebrska- Jesionek, D. and Stryjecka-Zimmer, M. (2006). [The role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in invasion of tumours of neuroepithelial tissue]. Neurol Neurochir Pol. 40:404-412
27. Boocock, D. J., Faust, G. E., Patel, K. R., Schinas, A. M., Brown, V. A., Ducharme, M. P., Booth, T. D., Crowell, J. A., Perloff, M., Gescher, A. J., Steward, W. P. and Brenner, D. E. (2007). Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev. 16:1246-1252
28. Brakenhielm, E., Cao, R. and Cao, Y. (2001). Suppression of angiogenesis, tumor growth, and wound healing by resveratrol, a natural compound in red wine and grapes. FASEB J. 15:1798-1800
29. Bruno, R. D. andNjar,V. C. (2007). Targeting cytochrome P450 enzymes: a new approach in anti-cancer drug development. Bioorg Med Chem. 15:5047-5060
30. Burcham, P. C. (1999). Internal hazards: baseline DNA damage by endogenous products of normal metabolism. Mutat Res. 443:11-36.
31. Burns, J., Yokota, T., Ashihara, H., Lean, M. E. and Crozier, A. (2002). Plant foods and herbal sources of resveratrol. J Agric Food Chem. 50:3337-3340
32. Cadenas, S. and Barja, G. (1999). Resveratrol, melatonin, vitamin E, and PBN protect against renal oxidative DNA damage induced by the kidney carcinogen KBrO3. Free Radic Biol Med. 26:1531-1537
33. Carbo, N., Costelli, P., Baccino, F. M., Lopez-Soriano, F. J. and Argiles, J. M. (1999). Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem Biophys Res Commun. 254:739-743
34. Casper, R. F., Quesne, M., Rogers, I. M., Shirota, T., Jolivet, A., Milgrom, E. and Savouret, J. F. (1999). Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol Pharmacol. 56:784-790
35. Celotti, E., Ferrarini, R., Zironi, R. and Conte, L. S. (1996). Resveratrol content of some wines obtained from driedValpolicella grapes:Recioto andAmarone. J Chromatogr A. 730:47-52.
36. Chan, M. M., Mattiacci, J. A., Hwang, H. S., Shah, A. and Fong, D. (2000). Synergy between ethanol and grape polyphenols, quercetin, and resveratrol, in the inhibition of the inducible nitric oxide synthase pathway. Biochem Pharmacol. 60:1539-1548
37. Chang, T. K., Lee, W. B. and Ko, H. H. (2000). Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen- activating human cytochrome P450 1B1. Can J Physiol Pharmacol. 78:874-881
38. Chen, F., Castranova, V., Shi, X. and Demers, L. M. (1999). New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem. 45:7-17.
39. Chugun, A., Uchide, T., Tsurimaki, C., Nagasawa, H., Sasaki, T., Ueno, S., Takagishi, K., Hara, Y. and Temma, K. (2008). Mechanisms responsible for reduced cardiotoxicity of mitoxantrone compared to Doxorubicin examined in isolated Guinea-pig heart preparations. J Vet Med Sci. 70:255-264
40. Chun, K. S., Cha, H. H., Shin, J. W., Na, H. K., Park, K. K., Chung, W. Y. and Surh, Y. J. (2004). Nitric oxide induces expression of cyclooxygenase-2 in mouse skin through activation of NF-kappaB. Carcinogenesis. 25:445-454
41. Chun, K. S., Keum, Y. S., Han, S. S., Song, Y. S., Kim, S. H. and Surh, Y. J. (2003). Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappaB activation. Carcinogenesis. 24:1515-1524
42. Ciolino, H. P. and Yeh, G. C. (1999). Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol Pharmacol. 56:760-767
43. Clement, M.V., Hirpara, J. L., Chawdhury, S. H. and Pervaiz, S. (1998). Chemopreventive agent resveratrol, a natural product derived from grapes, triggers CD95 signaling-dependent apoptosis in human tumor cells. Blood. 92:996-1002.
44. Coussens, L. M. and Werb, Z. (2002). Inflammation and cancer. Nature. 420:860-867
45. Crowell, J. A., Korytko, P. J., Morrissey, R. L., Booth, T. D. and Levine, B. S. (2004). Resveratrol-associated renal toxicity. Toxicol Sci. 82:614-619
46. de Santi, C., Pietrabissa, A., Mosca, F. and Pacifici, G. M. (2000). Glucuronidation of resveratrol, a natural product present in grape and wine, in the human liver. Xenobiotica. 30:1047-1054 (Pubitemid 32099176)
47. De Santi, C., Pietrabissa, A., Spisni, R., Mosca, F. and Pacifici, G. M. (2000). Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica. 30:609-617 (Pubitemid 30449570)
48. Delmas, D., Passilly-Degrace, P., Jannin, B., Cherkaoui Malki, M. and Latruffe, N. (2002). Resveratrol, a chemopreventive agent, disrupts the cell cycle control of human SW480 colorectal tumor cells. Int J Mol Med. 10:193-199
49. Delmas, D., Rebe, C., Lacour, S., Filomenko, R., Athias, A., Gambert, P., Cherkaoui-Malki, M., Jannin, B., Dubrez-Daloz, L., Latruffe, N. and Solary, E. (2003). Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem. 278:41482-41490
50. Do Amaral, C. L., Francescato, H. D., Coimbra, T. M., Costa, R. S., Darin, J. D., Antunes, L. M. and Bianchi, M. D. (2007). Resveratrol attenuates cisplatin-induced nephrotoxicity in rats. Arch Toxicol. 82:363-370
51. Donnelly, L. E., Newton, R., Kennedy, G. E., Fenwick, P. S., Leung, R. H., Ito, K., Russell, R. E. and Barnes, P. J. (2004). Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms. Am J Physiol Lung Cell Mol Physiol. 287:L774-83.
52. Dorai, T. and Aggarwal, B. B. (2004). Role of chemopreventive agents in cancer therapy. Cancer Lett. 215:129-140
53. Du, M. Q., Carmichael, P. L. and Phillips, D. H. (1994). Induction of activating mutations in the human c-Ha-ras-1 proto-oncogene by oxygen free radicals. Mol Carcinog. 11:170-175
54. Elleingand, E., Gerez, C., Un, S., Knupling, M., Lu, G., Salem, J., Rubin, H., Sauge-Merle, S., Laulhere, J. P. and Fontecave, M. (1998). Reactivity studies of the tyrosyl radical in ribonucleotide reductase fromMycobacterium tuberculosis and Arabidopsis thaliana-comparison with Escherichia coli and mouse. Eur J Biochem. 258:485-490
55. Estrov, Z., Shishodia, S., Faderl, S., Harris, D., Van, Q., Kantarjian, H. M., Talpaz, M. and Aggarwal, B. B. (2003). Resveratrol blocks interleukin-1betainduced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, causes S-phase arrest, and induces apoptosis of acute myeloid leukemia cells. Blood. 102:987-995
56. Fidler, I. J. (2000). Angiogenesis and cancer metastasis. Cancer J. 6 Suppl 2:S134-41.
57. Fitzpatrick, D. F., Hirschfield, S. L. and Coffey, R. G. (1993). Endotheliumdependent vasorelaxing activity of wine and other grape products. Am J Physiol. 265:H774-8.
58. Floreani, M., Napoli, E., Quintieri, L. and Palatini, P. (2003). Oral administration of trans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity. Life Sci. 72:2741-2750
59. Fontecave, M., Lepoivre, M., Elleingand, E., Gerez, C. and Guittet, O. (1998). Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 421:277-279
60. Fukuhara, K. and Miyata, N. (1998). Resveratrol as a new type of DNA-cleaving agent. Bioorg Med Chem Lett. 8:3187-3192
61. Fukuhara, K., Nagakawa, M., Nakanishi, I., Ohkubo, K., Imai, K., Urano, S., Fukuzumi, S., Ozawa, T., Ikota, N., Mochizuki, M., Miyata, N. and Okuda, H. (2006). Structural basis for DNA-cleaving activity of resveratrol in the presence of Cu(II). Bioorg Med Chem. 14:1437-1443
62. Gao, X., Xu, Y. X., Divine, G., Janakiraman, N., Chapman, R. A. and Gautam, S. C. (2002). Disparate in vitro and in vivo antileukemic effects of resveratrol, a natural polyphenolic compound found in grapes. J Nutr. 132:2076-2081
63. Gao, X., Xu, Y. X., Janakiraman, N., Chapman, R. A. and Gautam, S. C. (2001). Immunomodulatory activity of resveratrol: suppression of lymphocyte proliferation, development of cell-mediated cytotoxicity, and cytokine production. Biochem Pharmacol. 62:1299-1308
64. Garg, A. and Aggarwal, B. B. (2002). Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia. 16:1053-1068
65. Garvin, S., Ollinger, K. and Dabrosin, C. (2006). Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 231:113-122
66. Gescher, A. J. and Steward, W. P. (2003). Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomarkers Prev. 12:953-957
67. Giri, D. K. and Aggarwal, B. B. (1998). Constitutive activation of NF-kappaB causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates. J Biol Chem. 273:14008-14014
68. Giudice, A. and Montella, M. (2006). Activation of the Nrf2-ARE signaling pathway: a promising strategy in cancer prevention. Bioessays. 28: 169-181
69. Giuliani, N., Colla, S., Lazzaretti, M., Sala, R., Roti, G., Mancini, C., Bonomini, S., Lunghi, P., Hojden, M., Genestreti, G., Svaldi, M., Coser, P., Fattori, P. P., Sammarelli, G., Gazzola, G. C., Bataille, R., Almici, C., Caramatti, C., Mangoni, L. and Rizzoli, V. (2003). Proangiogenic properties of human myeloma cells: production of angiopoietin-1 and its potential relationship to myeloma-induced angiogenesis. Blood. 102:638-645.
70. Gius, D., Botero, A., Shah, S. and Curry, H. A. (1999). Intracellular oxidation/ reduction status in the regulation of transcription factors NF-kappaB and AP-1. Toxicol Lett. 106:93-106.
71. Goldberg, D. M., Yan, J., Ng, E., Diamandis, E. P., Karumanchiri, A., Soleas, G. and Waterhouse, A. L. (1995). A Global Survey of Trans-Resveratrol Concentrations in Commercial Wines. Am J Enol Vitic. 46:159-165.
72. Goldberg, D. M., Yan, J. and Soleas, G. J. (2003). Absorption of three winerelated polyphenols in three different matrices by healthy subjects. Clin Biochem. 36:79-87.
73. Gonzalez, F. J. (1992). Human cytochromes P450: problems and prospects. Trends Pharmacol Sci. 13:346-352
74. Gonzalez, F. J., Aoyama, T. and Gelboin, H. V. (1990). Activation of promutagens by human cDNA-expressed cytochrome P450s. Prog Clin Biol Res. 340B:77-86.
75. Gonzalez, F. J. and Gelboin, H. V. (1994). Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab Rev. 26:165-183
76. Goodwin, J. S. and Ceuppens, J. (1983). Regulation of the immune response by prostaglandins. J Clin Immunol. 3:295-315.
77. Gronbaek, M., Deis, A., Sorensen, T. I., Becker, U., Schnohr, P. and Jensen, G. (1995). Mortality associated with moderate intakes of wine, beer, or spirits. BMJ. 310:1165-1169
78. Guengerich, F. P. (1988). Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res. 48:2946-2954
79. Hain,R., Bieseler,B., Kindl, H., Schroder, G. and Stocker,R. (1990). Expression of a stilbene synthase gene in Nicotiana tabacum results in synthesis of the phytoalexin resveratrol. Plant Mol Biol. 15:325-335
80. Han, S. S., Keum, Y. S., Seo, H. J., Chun, K. S., Lee, S. S. and Surh, Y. J. (2001). Capsaicin suppresses phorbol ester-induced activation of NF-kappaB/Rel and AP-1 transcription factors in mouse epidermis. Cancer Lett. 164:119-126
81. Hebbar, V., Shen, G., Hu, R., Kim, B. R., Chen, C., Korytko, P. J., Crowell, J. A., Levine, B. S. and Kong, A. N. (2005). Toxicogenomics of resveratrol in rat liver. Life Sci. 76:2299-2314
82. Higinbotham, K. G., Rice, J. M., Diwan, B. A., Kasprzak, K. S., Reed, C. D. and Perantoni, A. O. (1992). GGT to GTT transversions in codon 12 of the K-ras oncogene in rat renal sarcomas induced with nickel subsulfide or nickel subsulfide/iron are consistent with oxidative damage to DNA. Cancer Res. 52:4747-4751
83. Hofmann, T. (2007). Tumorsupressor p53-guardian of the genome: product of the tumor supressor gene. Vorlesung Tumorbiologie, Universität Heidelberg, 4FS Molekulare Biotechnologie.
84. Hollstein, M., Sidransky, D., Vogelstein, B. and Harris, C. C. (1991). p53 mutations in human cancers. Science. 253:49-53.
85. Horvath, Z., Saiko, P., Illmer, C., Madlener, S., Hoechtl, T., Bauer,W., Erker, T., Jaeger, W., Fritzer-Szekeres, M. and Szekeres, T. (2005). Synergistic action of resveratrol, an ingredient of wine, with Ara-C and tiazofurin in HL-60 human promyelocytic leukemia cells. Exp Hematol. 33:329-335
86. Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L. L., Scherer, B. and Sinclair, D. A. (2003). Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature. 425:191-196
87. Hsieh, T. C., Juan, G., Darzynkiewicz, Z. and Wu, J. M. (1999). Resveratrol increases nitric oxide synthase, induces accumulation of p53 and p21(WAF1/CIP1), and suppresses cultured bovine pulmonary artery endothelial cell proliferation by perturbing progression through S and G2. Cancer Res. 59:2596-2601
88. Hu, X. and Xuan, Y. (2008). Bypassing cancer drug resistance by activating multiple death pathways - A proposal from the study of circumventing cancer drug resistance by induction of necroptosis. Cancer Lett. 259:127-137
89. Hu, Y., Sun, C. Y., Huang, J., Hong, L., Zhang, L. and Chu, Z. B. (2007). Antimyeloma effects of resveratrol through inhibition of angiogenesis. Chin Med J (Engl). 120:1672-1677
90. Hunter, T. and Pines, J. (1994). Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell. 79:573-582
91. Itzkowitz, S. H. and Yio, X. (2004). Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation. Am J Physiol Gastrointest Liver Physiol. 287:G7-17.
92. Jang, M., Cai, L., Udeani, G. O., Slowing, K. V., Thomas, C. F., Beecher, C.W., Fong, H. H., Farnsworth, N. R., Kinghorn, A. D., Mehta, R. G., Moon, R. C. and Pezzuto, J. M. (1997). Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:218-220
93. Jang, M. and Pezzuto, J. M. (1998). Effects of resveratrol on 12-Otetradecanoylphorbol- 13-acetate-induced oxidative events and gene expression in mouse skin. Cancer Lett. 134:81-89
94. Jazirehi, A. R. and Bonavida, B. (2004). Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 3:71-84.
95. Jeong, W. S., Kim, I. W., Hu, R. and Kong, A. N. (2004). Modulation of AP-1 by natural chemopreventive compounds in human colon HT-29 cancer cell line. Pharm Res. 21:649-660
96. Jo, H., Zhang, R., Zhang, H., McKinsey, T. A., Shao, J., Beauchamp, R. D., Ballard, D. W. and Liang, P. (2000). NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. Oncogene. 19:841-849
97. Karin, M. and Delhase, M. (2000). The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol. 12:85-98.
98. Kensler, T.W. (1997). Chemoprevention by inducers of carcinogen detoxication enzymes. Environ Health Perspect. 105 Suppl 4:965-970
99. Kim, S. O., Kundu, J. K., Shin, Y. K., Park, J. H., Cho, M. H., Kim, T. Y. and Surh, Y. J. (2005). [6]-Gingerol inhibits COX-2 expression by blocking the activation of p38 MAP kinase and NF-kappaB in phorbol ester-stimulated mouse skin. Oncogene. 24:2558-2567
100. Kim, Y. A., Choi, B. T., Lee, Y. T., Park, D. I., Rhee, S. H., Park, K. Y. and Choi, Y. H. (2004). Resveratrol inhibits cell proliferation and induces apoptosis of human breast carcinoma MCF-7 cells. Oncol Rep. 11:441-446
101. Kim, Y. A., Lee, W. H., Choi, T. H., Rhee, S. H., Park, K. Y. and Choi, Y. H. (2003). Involvement of p21WAF1/CIP1, pRB, Bax and NF-kappaB in induction of growth arrest and apoptosis by resveratrol in human lung carcinoma A549 cells. Int J Oncol. 23:1143-1149
102. Kim, Y. A., Rhee, S. H., Park, K. Y. and Choi, Y. H. (2003). Antiproliferative effect of resveratrol in human prostate carcinoma cells. J Med Food. 6:273-280
103. Kimura, Y. and Okuda, H. (2000). Effects of naturally occurring stilbene glucosides from medicinal plants and wine, on tumour growth and lung metastasis in Lewis lung carcinoma-bearing mice. J Pharm Pharmacol. 52:1287-1295
104. Kimura, Y. and Okuda, H. (2001). Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr. 131:1844-1849
105. Kode, A., Rajendrasozhan, S., Caito, S., Yang, S. R.,Megson, I. L. and Rahman, I. (2007). Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells. Am J Physiol Lung Cell Mol Physiol. 294:478-488
106. Kode, A., Yang, S. R. and Rahman, I. (2006). Differential effects of cigarette smoke on oxidative stress and proinflammatory cytokine release in primary human airway epithelial cells and in a variety of transformed alveolar epithelial cells. Respir Res. 7:132.
107. Kufe, D., Pollock, R., Weichselbaum, R., Bast, R. Jr., Gasler, T., Holland, J., Frei, E. (2003). Holland-Frei Cancer Medicine 6. BC Decker, Ontario
108. Kumar V, A. A., Fausto N. (2004). Robbins and Cotran Pathologic basis of disease. Elsevier Saunders, Philadelphia.
109. Kundu, J. K., Chun, K. S., Kim, S. O. and Surh, Y. J. (2004). Resveratrol inhibits phorbol ester-induced cyclooxygenase-2 expression in mouse skin: MAPKs and AP-1 as potential molecular targets. Biofactors. 21:33-39
110. Kundu, J. K., Shin, Y. K., Kim, S. H. and Surh, Y. J. (2006). Resveratrol inhibits phorbol ester-induced expression of COX-2 and activation of NF-kappaB in mouse skin by blocking IkappaB kinase activity. Carcinogenesis. 27:1465-1474
111. Kundu, J. K., Shin, Y. K. and Surh, Y. J. (2006). Resveratrol modulates phorbol ester-induced pro-inflammatory signal transduction pathways in mouse skin in vivo: NF-kappaB and AP-1 as prime targets. Biochem Pharmacol. 72:1506-1515
112. Kuper, H., Adami, H. O. and Trichopoulos, D. (2000). Infections as a major preventable cause of human cancer. J Intern Med. 248:171-183
113. Kuroiwa, Y., Nishikawa, A., Kitamura, Y., Kanki, K., Ishii, Y., Umemura, T. and Hirose, M. (2006). Protective effects of benzyl isothiocyanate and sulforaphane but not resveratrol against initiation of pancreatic carcinogenesis in hamsters. Cancer Lett. 241:275-280
114. Lala, P. K. and Chakraborty, C. (2001). Role of nitric oxide in carcinogenesis and tumour progression. Lancet Oncol. 2:149-156
115. LaMontagne, K. R., Jr., Moses, M. A., Wiederschain, D., Mahajan, S., Holden, J., Ghazizadeh, H., Frank, D. A. and Arbiser, J. L. (2000). Inhibition ofMAP kinase kinase causes morphological reversion and dissociation between soft agar growth and in vivo tumorigenesis in angiosarcoma cells. Am J Pathol. 157:1937-1945
116. Langcake, P. and Pryce, R. J. (1976). The production of resveratrol by Vitis Vinifera and other members of the Vitaceae as a response to infection or injury. Physiol Plant Pathol. 9:77-86.
117. Lee, J. E. and Safe, S. (2001). Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem Pharmacol. 62:1113-1124
118. Leiro, J., Alvarez, E., Arranz, J. A., Laguna, R., Uriarte, E. and Orallo, F. (2004). Effects of cis-resveratrol on inflammatory murine macrophages: antioxidant activity and down-regulation of inflammatory genes. J Leukoc Biol. 75:1156-1165
119. Lekakis, J., Rallidis, L. S., Andreadou, I., Vamvakou, G., Kazantzoglou, G., Magiatis, P., Skaltsounis, A. L. and Kremastinos, D. T. (2005). Polyphenolic compounds from red grapes acutely improve endothelial function in patients with coronary heart disease. Eur J Cardiovasc Prev Rehabil. 12:596-600.
120. Leonard, S. S., Xia, C., Jiang, B. H., Stinefelt, B., Klandorf, H., Harris, G. K. and Shi, X. (2003). Resveratrol scavenges reactive oxygen species and effects radical-induced cellular responses. Biochem Biophys Res Commun. 309:1017-1026
121. Li, Z. G., Hong, T., Shimada, Y., Komoto, I., Kawabe, A., Ding, Y., Kaganoi, J., Hashimoto, Y. and Imamura, M. (2002). Suppression of Nnitrosomethylbenzylamine (NMBA)-induced esophageal tumorigenesis in F344 rats by resveratrol. Carcinogenesis. 23:1531-1536
122. Liang, Y. C., Tsai, S. H., Chen, L., Lin-Shiau, S. Y. and Lin, J. K. (2003). Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochem Pharmacol. 65:1053-1060
123. Lin, M. T., Yen, M. L., Lin, C. Y. and Kuo, M. L. (2003). Inhibition of vascular endothelial growth factor-induced angiogenesis by resveratrol through interruption of Src-dependent vascular endothelial cadherin tyrosine phosphorylation. Mol Pharmacol. 64:1029-1036
124. Liu, Z. G., Hsu, H., Goeddel, D. V. and Karin, M. (1996). Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death. Cell. 87:565-576
125. Luque, I. and Gelinas, C. (1997). Rel/NF-kappa B and I kappa B factors in oncogenesis. Semin Cancer Biol. 8:103-111
126. Lyons, M. M., Yu, C., Toma, R. B., Cho, S. Y., Reiboldt, W., Lee, J. and van Breemen, R. B. (2003). Resveratrol in raw and baked blueberries and bilberries. J Agric Food Chem. 51:5867-5870
127. Manna, S. K., Mukhopadhyay, A. and Aggarwal, B. B. (2000). Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation. J Immunol. 164:6509-6519
128. Marx, J. (2004). Cancer research. Inflammation and cancer: the link grows stronger. Science. 306:966-968
129. Meng, X., Maliakal, P., Lu, H., Lee, M. J. and Yang, C. S. (2004). Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. J Agric Food Chem. 52: 935-942
130. Mertens-Talcott, S. U. and Percival, S. S. (2005). Ellagic acid and quercetin interact synergistically with resveratrol in the induction of apoptosis and cause transient cell cycle arrest in human leukemia cells. Cancer Lett. 218:141-151
131. Metcalf, D. (1989). The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells. Nature. 339:27-30.
132. Miura, D., Miura, Y. and Yagasaki, K. (2003). Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci. 73:1393-1400
133. Miyashita, T., Krajewski, S., Krajewska, M., Wang, H. G., Lin, H. K., Liebermann, D. A., Hoffman, B. and Reed, J. C. (1994). Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene. 9:1799-1805
134. Moller, P. andWallin, H. (1998). Adduct formation, mutagenesis and nucleotide excision repair ofDNAdamage produced by reactive oxygen species and lipid peroxidation product. Mutat Res. 410:271-290
135. Mollerup, S., Ovrebo, S. and Haugen, A. (2001). Lung carcinogenesis: resveratrol modulates the expression of genes involved in the metabolism of PAH in human bronchial epithelial cells. Int J Cancer. 92:18-25.
136. Morgan, D. O. (1995). Principles of CDK regulation. Nature. 374:131-134
137. Mousa, S. S. and Mousa, S. A. (2005). Effect of resveratrol on angiogenesis and platelet/fibrin-accelerated tumor growth in the chick chorioallantoic membrane model. Nutr Cancer. 52:59-65.
138. Muller-Decker, K., Neufang, G., Berger, I., Neumann, M.,Marks, F. and Furstenberger, G. (2002). Transgenic cyclooxygenase-2 overexpression sensitizes mouse skin for carcinogenesis. Proc Natl Acad Sci U S A. 99:12483-12488
139. Muller-Decker, K., Scholz, K., Marks, F. and Furstenberger, G. (1995). Differential expression of prostaglandin H synthase isozymes during multistage carcinogenesis in mouse epidermis. Mol Carcinog. 12:31-41.
140. Narayanan, B. A., Narayanan, N. K., Re, G. G. and Nixon, D. W. (2003). Differential expression of genes induced by resveratrol in LNCaP cells: P53- mediated molecular targets. Int J Cancer. 104:204-212
141. Nelson,W. G., De Marzo, A. M., DeWeese, T. L. and Isaacs,W. B. (2004). The role of inflammation in the pathogenesis of prostate cancer.JUrol. 172:S6-11; discussion S11-2.
142. Nonn, L., Duong, D. and Peehl, D. M. (2007). Chemopreventive anti- inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. Carcinogenesis. 28:1188-1196
143. Nurse, P. (1997). Checkpoint pathways come of age. Cell. 91:865-867
144. O'Byrne, K. J. and Dalgleish, A. G. (2001). Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer. 85:473-483
145. Olinski, R., Zastawny, T., Budzbon, J., Skokowski, J., Zegarski, W. and Dizdaroglu, M. (1992). DNA base modifications in chromatin of human cancerous tissues. FEBS Lett. 309:193-198
146. Ovesna, Z., Kozics, K., Bader, Y., Saiko, P., Handler, N., Erker, T. and Szekeres, T. (2006). Antioxidant activity of resveratrol, piceatannol and 3,3-,4,4-,5,5-- hexahydroxy-trans-stilbene in three leukemia cell lines. Oncol Rep. 16:617-624
147. Pacek, M., Prokhorova, T. A. and Walter, J. C. (2004). Cdk1: unsung hero of S phase? Cell Cycle. 3:401-403
148. Pagano, M., Pepperkok, R., Lukas, J., Baldin, V., Ansorge, W., Bartek, J. and Draetta, G. (1993). Regulation of the cell cycle by the cdk2 protein kinase in cultured human fibroblasts. J Cell Biol. 121:101-111 (Pubitemid 23981141)
149. Pendurthi, U. R. and Rao, L. V. (2002). Resveratrol suppresses agonistinduced monocyte adhesion to cultured human endothelial cells. Thromb Res. 106:243-248
150. Pinelo, M., Manzocco, L., Nunez, M. J. and Nicoli, M. C. (2004). Interaction among phenols in food fortification: negative synergism on antioxidant capacity. J Agric Food Chem. 52:1177-1180
151. Piver, B., Berthou, F., Dreano, Y. and Lucas, D. (2001). Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components. Toxicol Lett. 125:83-91.
152. Pozo-Guisado, E., Alvarez-Barrientos, A., Mulero-Navarro, S., Santiago- Josefat, B. and Fernandez-Salguero, P. M. (2002). The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochem Pharmacol. 64:1375-1386
153. Qiao, L., Kozoni, V., Tsioulias, G. J., Koutsos, M. I., Hanif, R., Shiff, S. J. and Rigas, B. (1995). Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta. 1258:215-223
154. Ragione, F. D., Cucciolla, V., Criniti, V., Indaco, S., Borriello, A. and Zappia, V. (2003). p21Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect. J Biol Chem. 278:23360-23368
155. Raptis, S. and Bapat, B. (2006). Genetic instability in human tumors. EXS. 303-320
156. Revel, A., Raanani, H., Younglai, E., Xu, J., Rogers, I., Han, R., Savouret, J. F. and Casper, R. F. (2003). Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. J Appl Toxicol. 23:255-261
157. Rezk, Y. A., Balulad, S. S., Keller, R. S. and Bennett, J. A. (2006). Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Am J Obstet Gynecol. 194:e23-6.
158. Ribeiro de Lima, M. T., Waffo-Teguo, P., Teissedre, P. L., Pujolas, A., Vercauteren, J., Cabanis, J. C. and Merillon, J. M. (1999). Determination of stilbenes (trans-astringin, cis- and trans-piceid, and cis- and trans-resveratrol) in Portuguese wines. J Agric Food Chem. 47:2666-2670
159. Richard, J. L. (1987). [Coronary risk factors. The French paradox]. Arch Mal Coeur Vaiss. 80 Spec No:17-21.
160. Rigas, B., Goldman, I. S. and Levine, L. (1993). Altered eicosanoid levels in human colon cancer. J Lab Clin Med. 122:518-523
161. Rimsza, L., Pastos, K., Massey, K. and Braylan, R. (2003). Endothelial stimulation by small lymphocytic lymphoma correlates with secreted levels of basic fibroblastic growth factor. Br J Haematol. 120:753-758
162. Sagar, S. M., Yance, D. and Wong, R. K. (2006). Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 1. Curr Oncol. 13:14-26.
163. Sanders, T. H., McMichael, R. W., Jr. and Hendrix, K. W. (2000). Occurrence of resveratrol in edible peanuts. J Agric Food Chem. 48:1243-1246
164. Schneider, Y., Duranton, B., Gosse, F., Schleiffer, R., Seiler, N. and Raul, F. (2001). Resveratrol inhibits intestinal tumorigenesis and modulates hostdefense- related gene expression in an animal model of human familial adenomatous polyposis. Nutr Cancer. 39:102-107
165. Sengottuvelan, M., Viswanathan, P. and Nalini, N. (2006). Chemopreventive effect of trans-resveratrol-a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis. 27:1038-1046
166. Shen, M. Y., Hsiao, G., Liu, C. L., Fong, T. H., Lin, K. H., Chou, D. S. and Sheu, J. R. (2007). Inhibitory mechanisms of resveratrol in platelet activation: pivotal roles of p38 MAPK and NO/cyclic GMP. Br J Haematol. 139:475-485
167. Siemann, E. H. and Creasy, L. L. (1992). Concentration of the phytoalexin resveratrol in wine. Am Soc Enol Viticulture. 43:49-52.
168. Singh, R. P. and Agarwal, R. (2007). Inducible nitric oxide synthase-vascular endothelial growth factor axis: a potential target to inhibit tumor angiogenesis by dietary agents. Curr Cancer Drug Targets. 7:475-483
169. Singh, S. U., Casper, R. F., Fritz, P. C., Sukhu, B., Ganss, B., Girard, B., Jr., Savouret, J. F. and Tenenbaum, H. C. (2000). Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol. J Endocrinol. 167:183-195
170. Sizemore, N., Lerner, N., Dombrowski, N., Sakurai, H. and Stark, G. R. (2002). Distinct roles of the Ikappa B kinase alpha and beta subunits in liberating nuclear factor kappa B (NF-kappa B) from Ikappa B and in phosphorylating the p65 subunit of NF-kappa B. J Biol Chem. 277:3863-3869
171. Sonenshein, G. E. (1997). Rel/NF-kappa B transcription factors and the control of apoptosis. Semin Cancer Biol. 8:113-119
172. Srinivasula, S. M., Datta, P., Fan, X. J., Fernandes-Alnemri, T., Huang, Z. and Alnemri, E. S. (2000). Molecular determinants of the caspase-promoting activity of Smac/DIABLO and its role in the death receptor pathway. J Biol Chem. 275:36152-36157
173. Stewart, J. R., Artime, M. C. and O'Brian, C. A. (2003). Resveratrol: a candidate nutritional substance for prostate cancer prevention. J Nutr. 133:2440S- 2443S.
174. Stivala, L. A., Savio, M., Carafoli, F., Perucca, P., Bianchi, L., Maga, G., Forti, L., Pagnoni, U. M., Albini, A., Prosperi, E. and Vannini, V. (2001). Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem. 276:22586-22594
175. Sun, X. F. and Zhang, H. (2007). NFKB and NFKBI polymorphisms in relation to susceptibility of tumour and other diseases. Histol Histopathol. 22:1387-1398
176. Surh, Y. J. (2003). Cancer chemoprevention with dietary phytochemicals. Nat Rev Cancer. 3:768-780
177. Surh, Y. J., Chun, K. S., Cha, H. H., Han, S. S., Keum, Y. S., Park, K. K. and Lee, S. S. (2001). Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOSthrough suppression of NF-kappaBactivation. Mutat Res. 480-481: 243-268
178. Surh, Y. J., Hurh, Y. J., Kang, J. Y., Lee, E., Kong, G. and Lee, S. J. (1999). Resveratrol, an antioxidant present in red wine, induces apoptosis in human promyelocytic leukemia (HL-60) cells. Cancer Lett. 140:1-10.
179. Szaefer, H., Cichocki, M., Brauze, D. and Baer-Dubowska, W. (2004). Alteration in phase I and II enzyme activities and polycyclic aromatic hydrocarbons-DNA adduct formation by plant phenolics in mouse epidermis. Nutr Cancer. 48:70-77
180. Tessitore, L., Davit, A., Sarotto, I. and Caderni, G. (2000). Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis. 21:1619-1622
181. Theodosiou, A., Smith, A., Gillieron, C.,Arkinstall, S. andAshworth, A. (1999). MKP5, a new member of the MAP kinase phosphatase family, which selectively dephosphorylates stress-activated kinases. Oncogene. 18:6981-6988
182. Tiano, H. F., Loftin, C. D., Akunda, J., Lee, C. A., Spalding, J., Sessoms, A., Dunson, D. B., Rogan, E. G., Morham, S. G., Smart, R. C. and Langenbach, R. (2002). Deficiency of either cyclooxygenase (COX)-1 or COX-2 alters epidermal differentiation and reduces mouse skin tumorigenesis. Cancer Res. 62:3395-3401
183. Trela, B. C. andWaterhouse, A. L. (1996). Resveratrol: isomeric molar absorptivities and stability. J Agric Food Chem. 44:1253-1257.
184. Tsai, S. H., Lin-Shiau, S. Y. and Lin, J. K. (1999). Suppression of nitric oxide synthase and the down-regulation of the activation of NFkappaB in macrophages by resveratrol. Br J Pharmacol. 126:673-680
185. Tseng, S.-H., Lin, S.-M., Chen, J.-C., Su, Y.-H., Huang, H.-Y., Chen, C.-K., Lin, P.-Y. and Chen, Y. (2004). Resveratrol suppresses the angiogenesis and tumor growth of gliomas in rats. Clin Cancer Res. 10:2190-2202.
186. Tsujii, M. and DuBois, R. N. (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 83:493-501.
187. Vaca, C. E., Wilhelm, J. and Harms-Ringdahl, M. (1988). Interaction of lipid peroxidation products with DNA. A review. Mutat Res. 195:137-149
188. Vacca, A., Ribatti, D., Presta, M.,Minischetti, M., Iurlaro, M.,Ria, R.,Albini, A., Bussolino, F. and Dammacco, F. (1999). Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple myeloma. Blood. 93:3064-3073
189. van Antwerp, D. J., Martin, S. J., Kafri, T., Green, D. R. and Verma, I. M. (1996). Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science. 274:787-789
190. van Ginkel, P. R., Sareen, D., Subramanian, L., Walker, Q., Darjatmoko, S. R., Lindstrom, M. J., Kulkarni, A., Albert, D. M. and Polans, A. S. (2007). Resveratrol inhibits tumor growth of human neuroblastoma and mediates apoptosis by directly targeting mitochondria. Clin Cancer Res. 13: 5162-5169
191. Vanderveen, E. E., Grekin, R. C., Swanson, N. A. and Kragballe, K. (1986). Arachidonic acid metabolites in cutaneous carcinomas. Evidence suggesting that elevated levels of prostaglandins in basal cell carcinomas are associated with an aggressive growth pattern. Arch Dermatol. 122:407-412
192. Vitaglione, P., Sforza, S., Galaverna, G., Ghidini, C., Caporaso, N., Vescovi, P. P., Fogliano, V. and Marchelli, R. (2005). Bioavailability of trans-resveratrol from red wine in humans. Mol Nutr Food Res. 49:495-504.
193. Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E., Jr. and Walle, U. K. (2004). High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab Dispos. 32:1377-1382
194. Wang, C. Y., Mayo, M. W. and Baldwin, A. S., Jr. (1996). TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. Science. 274:784-787
195. Wang, Y., Catana, F., Yang, Y., Roderick, R. and van Breemen, R. B. (2002). An LC-MS method for analyzing total resveratrol in grape juice, cranberry juice, and in wine. J Agric Food Chem. 50:431-435
196. Wang, Z., Zou, J., Cao, K., Hsieh, T. C., Huang, Y. and Wu, J. M. (2005). Dealcoholized red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. Int J Mol Med. 16:533-540
197. Weidner, N., Folkman, J., Pozza, F., Bevilacqua, P., Allred, E. N., Moore, D. H., Meli, S. and Gasparini, G. (1992). Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 84:1875-1887
198. Wenzel, E., Soldo, T., Erbersdobler, H. and Somoza, V. (2005). Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. Mol Nutr Food Res. 49:482-494
199. Whitcomb, D. C. (2004). Inflammation and Cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 287: G315-9.
200. Wild, D. and Degen, G. H. (1987). Prostaglandin H synthase-dependent mutagenic activation of heterocyclic aromatic amines of the IQ-type. Carcinogenesis. 8:541-545
201. Wolter, F., Akoglu, B., Clausnitzer, A. and Stein, J. (2001). Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J Nutr. 131:2197-2203
202. Wu, C. C., Wu, C. I., Wang, W. Y. and Wu, Y. C. (2007). Low concentrations of resveratrol potentiate the antiplatelet effect of prostaglandins. Planta Med. 73:439-443
203. Yamanishi, Y., Boyle, D. L., Rosengren, S., Green, D. R., Zvaifler, N. J. and Firestein, G. S. (2002). Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc Natl Acad Sci U S A. 99:10025-10030
204. Yance, D. R., Jr. and Sagar, S.M. (2006). Targeting angiogenesiswith integrative cancer therapies. Integr Cancer Ther. 5:9-29.
205. Yen, G. C., Duh, P. D. and Lin, C. W. (2003). Effects of resveratrol and 4- hexylresorcinol on hydrogen peroxide-induced oxidative DNA damage in human lymphocytes. Free Radic Res. 37:509-514
206. Yoshida, D., Ikeda, Y. and Nakazawa, S. (1993). Quantitative analysis of copper, zinc and copper/zinc ratio in selected human brain tumors. J Neurooncol. 16:109-115
207. Yu, C., Shin, Y. G., Chow, A., Li, Y., Kosmeder, J. W., Lee, Y. S., Hirschelman, W. H., Pezzuto, J. M., Mehta, R. G. and van Breemen, R. B. (2002). Human, rat, and mouse metabolism of resveratrol. Pharm Res. 19:1907-1914
208. Yu, C., Shin, Y. G., Kosmeder, J. W., Pezzuto, J. M. and van Breemen, R. B. (2003). Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate. Rapid Commun Mass Spectrom. 17:307-313
209. Zell, J. A., McEligot, A. J., Ziogas, A., Holcombe, R. F. and Anton-Culver, H. (2007). Differential effects of wine consumption on colorectal cancer outcomes based on family history of the disease. Nutr Cancer. 59:36-45.
210. Zern, T. L., West, K. L. and Fernandez, M. L. (2003). Grape polyphenols decrease plasma triglycerides and cholesterol accumulation in the aorta of ovariectomized guinea pigs. J Nutr. 133:2268-2272
211. Zhang, P.,Li, H.,Wu,M.L., Chen,X.Y.,Kong, Q.Y.,Wang, X.W., Sun,Y.,Wen, S. and Liu, J. (2006). c-Myc downregulation: a critical molecular event in resveratrol-induced cell cycle arrest and apoptosis of humanmedulloblastoma cells. J Neurooncol. 80:123-131
212. Zhang, S., Cao, H. J., Davis, F. B., Tang, H. Y., Davis, P. J. and Lin, H. Y. (2004). Oestrogen inhibits resveratrol-induced post-translational modification of p53 and apoptosis in breast cancer cells. Br J Cancer. 91:178-185
213. Zhou, S., Yung Chan, S., Cher Goh, B., Chan, E., Duan, W., Huang, M. and McLeod, H. L. (2005).Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet. 44:279-304.
214. Zini, R., Morin, C., Bertelli, A., Bertelli, A. A. and Tillement, J. P. (1999). Effects of resveratrol on the rat brain respiratory chain. Drugs Exp Clin Res. 25:87-97.